Abstract: Porous microcomposites comprising a perfluorinated ion-exchange polymer (PFIEP) containing pendant metal cation exchanged sulfonate groups, metal cation exchanged carboxylate groups, or metal cation exchanged sulfonate and carboxylate groups, wherein the metal cation may be ligand coordinated, and optionally pendant sulfonic acid groups, carboxylic acid groups, or sulfonic acid and carboxylic acid groups, the PFIEP being entrapped within and highly dispersed throughout a network of metal oxide, a network of silica or a network of metal oxide and silica can be prepared from PFIEP and one or more precursors selected from the group consisting of a metal oxide precursor, a silica precursor, and a metal oxide and silica precursor using an in situ process. Preferred metal cations are Cr, Sn, Al, Fe, Os, Co, Zn, Hg, Li, Na, Cu, Pd or Ru. Such microcomposites have a first set of pores having a pore size diameter ranging from about 0.

Abstract: Catalyst comprising a perfluorinated ion-exchange microcomposite can be reactivated upon contact with at least one cleaning agent, such as an oxidizing agent, organic solvent, supercritical fluid or detergent. The process may further comprise heating prior to, during or after contact followed by washing with water and/or an organic solvent.

Abstract: This invention concerns modified fluorosulfonic acid compounds possessing a sulfonic acid fluoride, chloride or ester group or a sulfonic acid or a salt of a sulfonic acid group at one end and respectively a hydrolyzable or hydrolyzed silane group at the other end, said sulfonic group being adjacent a substantially fluorinated bidentate hydrocarbylene group which is in turn adjacent to a hydrocarbylenegroup linked to said hydrolyzable or hydrolyzed silane group. Self-condensation of the latter compounds provides novel siloxanes and polysiloxanes. This invention further concerns novel composites comprising a metal oxide network having incorporated therein a group having the formula: --O).sub.q Si(OH).sub.n-q R.sup.1.sub.m R.sup.2 R.sub.f SO.sub.3 Q, and compositions comprising a solid material having a reactive surface to which surface is attached at least one group having the formula: --O).sub.q Si(OH).sub.n-q R.sup.1.sub.m R.sup.2 R.sub.f SO.sub.3 Q.

Abstract: Porous microcomposites have been prepared from perfluorinated ion-exchange polymer and metal oxides such as silica using a sol-gel process. Such microcomposites possess high surface area and exhibit extremely high catalytic activity. Isomerization of terminal olefins is possible with such porous microcomposites.

Abstract: The present invention provides anti-neoplastic topoisomerase I inhibitors of the formula: ##STR1## wherein Ar is (C.sub.6 -C.sub. 12)aryl or (6- to 12-membered) heteroaryl comprising 1-3 N, S or non-peroxide O, wherein N is unsubstituted or is substituted with (C.sub.1 -C.sub.4)alkyl; X is H, CN, CHO, OH, acetyl, CF.sub.3, OCH.sub.3, NO.sub.2 or NH.sub.2 ; each Y is individually H, (C.sub.1 -C.sub.4)alkyl or aralkyl; Y' is H or (C.sub.1 -C.sub.4)alkyl; n is 0 or 1; or a pharmaceutically acceptable salt therein.

Abstract: This invention concerns a modified porous microcomposite comprising a perfluorinated ion-exchange polymer entrapped within and highly dispersed throughout a network of inorganic oxide wherein the network and optionally the pendant groups of the polymer have been modified with a Lewis acid. These modified microcomposites can be used in catalyst compositions for various chemical processes, such as in the alkylation or acylation of aromatics.

Abstract: Porous microcomposites comprising a perfluorinated ion-exchange polymer (PFIEP) containing pendant metal cation exchanged sulfonate groups, metal cation exchanged carboxylate groups, or metal cation exchanged sulfonate and carboxylate groups, wherein the metal cation may be ligand coordinated, and optionally pendant sulfonic acid groups, carboxylic acid groups, or sulfonic acid and carboxylic acid groups, the PFIEP being entrapped within and highly dispersed throughout a network of metal oxide, a network of silica or a network of metal oxide and silica can be prepared from PFIEP and one or more precursors selected from the group consisting of a metal oxide precursor, a silica precursor, and a metal oxide and silica precursor using an in situ process. Preferred metal cations are Cr, Sn, Al, Fe, Os, Co, Zn, Hg, Li, Na, Cu, Pd or Ru. Such microcomposites have a first set of pores having a pore size diameter ranging from about 0.

Abstract: Porous microcomposites comprising a perfluorinated ion-exchange polymer (PFIEP) containing pendant sulfonic acid and/or carboxylic acid groups entrapped within and highly dispersed throughout a network of metal oxide, a network of silica, or a network of metal oxide and silica are prepared from PFIEP and one or more precursors selected from the group consisting of a metal oxide precursor, a silica precursor, and a metal oxide and silica precursor using an in situ process. Such microcomposites have a first set of pores having a pore size diameter ranging from about 0.5 nm to about 75 nm and may further comprise a second set of pores having a diameter ranging from about 75 nm to about 1000 nm. These microcomposites possess high surface area and exhibit high catalytic activity for a variety of reactions including, but not limited to, nitrations, esterifications, dimerizations, alkylations, polymerizations, acylations, and isomerizations.

Abstract: The present invention provides anti-neoplastic topoisomerase I inhibitors of the formula: ##STR1## wherein Ar is (C.sub.6 -C.sub.12)aryl or (6- to 12-membered) heteroaryl comprising 1-3 N, S or non-peroxide O, wherein N is unsubstituted or is substituted with (C.sub.1 -C.sub.4)alkyl; X is H, CN, CHO, OH, acetyl, CF.sub.3, OCH.sub.3, NO.sub.2 or NH.sub.2 ; each Y is individually H, (C.sub.1 -C.sub.4)alkyl or aralkyl; Y' is H or (C.sub.1 -C.sub.4)alkyl; n is 0 or 1; or a pharmaceutically acceptable salt therein.

Abstract: The present invention provides a method of treatment of fungal infection with an antifungal topoisomerase I inhibitor of the formula: ##STR1## wherein Ar is (C.sub.6 -C.sub.12)aryl, a (5- to 12-membered) heteroaryl comprising 1-3 N, S or non-peroxide O, wherein N is unsubstituted or is substituted with H, (C.sub.1 -C.sub.4)alkyl or benzyl; or benzo; X is H, CN, CHO, OH, acetyl, CF.sub.3, O(C.sub.1 -C.sub.4)alkyl, NO.sub.2, NH.sub.2, halogen or halo-(C.sub.1 -C.sub.4)alkyl; each Y is individually H, (C.sub.1 -C.sub.4)alkyl or aralkyl; Y' is H or (C.sub.1 -C.sub.4)alkyl; n is 0 or 1; and each Z is individually H, (C.sub.1 -C.sub.4)alkyl, halogen or halo(C.sub.1 -C.sub.4)alkyl; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides anti-neoplastic topoisomerase I inhibitors of the formula: ##STR1## wherein Ar is (C.sub.6 -C.sub.12)aryl or (5- to 12-membered) heteroaryl comprising 1-3 N, S or non-peroxide O, wherein N is unsubstituted or is substituted with (C.sub.1 -C.sub.4)alkyl; X is H, CN, CHO, OH, acetyl, CF.sub.3, O(C.sub.1 -C.sub.4)alkyl, NO.sub.2, NH.sub.2, halogen or halo-(C.sub.1 -C.sub.4)alkyl; each Y is individually H, (C.sub.1 -C.sub.4)alkyl or aralkyl; Y' is H or (C.sub.1 -C.sub.4)alkyl; n is 0 or 1; and each Z is individually H, (C.sub.1 -C.sub.4)alkyl, halogen or halo(C.sub.1 -C.sub.4)alkyl; or a pharmaceutically acceptable salt therein.